Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingeniera Genetica Y Biotecnologia

Ingrid Rojas Constantin

Jorge Sotolongo Pena

Gerardo Enrique Guillen Nieto

Jorge Amador Berlanga Acosta

Gerardo Enrique Guillén Nieto

Luis Saturnino Herrera Martinez

Haydee Geronimo Perez

Jose Ignacio Fernandez Montequin

Hector Santana Milian

Luis Herrera Martínez

Larissa Chacon Corvea

Haydee Gerónimo Pérez

Leonardo Canan-Haden Frias

Jorge Berlanga Acosta

Larissa Chacón Corvea

Neobalis Franco Perez

Leonardo Canan-Haden Frías

José I Fernández Montequin

Calixto Valdés Pérez

Neobalis Franco Pérez

Calixto Valdes Perez

Héctor Santana Milián

The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favoring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrization of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrize and/or heal.

Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention

The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favouring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrisation of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrise and/or heal.

Methods for enhancing healing of diabetic foot ulcers by injecting epidermal growth factor (EGF)

Growing community of inventors

Ciudad de la Habana, Cuba

Ingrid Rojas Constantin